Uptravi 60 Tabs 800 mcg
60 Tabs — 800 mcg
Uptravi (selexipag) is a prescription medication used to treat adults with pulmonary arterial hypertension (PAH) to help improve exercise capacity and delay disease progression.
- Active ingredient: Selexipag
Uptravi is a revolutionary new medication for the treatment of pulmonary arterial hypertension (PAH). It works by inhibiting a specific enzyme called phosphodiesterase type 5 (PDE-5), which is involved in the narrowing of blood vessels in the lungs. This narrowing, called pulmonary vasoconstriction, is a major cause of PAH and can lead to serious and life-threatening conditions. By blocking the enzyme, Uptravi helps to relax the blood vessels in the lungs, allowing for better blood flow and improved breathing. Uptravi also helps to reduce symptoms associated with PAH, including chest pain, dizziness, fatigue, and shortness of breath. Uptravi is a once-daily pill that is easy to take, and it does not need to be taken with food.
It has been tested in clinical trials for safety and efficacy, and has been found to be both safe and effective in treating PAH. Uptravi is the first and only PDE-5 inhibitor approved for the treatment of PAH, providing a new and innovative option for treating this complex and often life-threatening condition.